Sandoz to acquire ranibizumab biosimilar from Coherus
Click Here to Manage Email Alerts
Key takeaways:
- Cimerli is a ranibizumab biosimilar.
- Sandoz will pay $170 million in cash for the biosimilar.
Sandoz has signed an agreement to acquire ranibizumab biosimilar Cimerli from Coherus BioSciences, according to a press release.
The $170 million cash deal includes a biologics license application, product inventory, ophthalmology sales and field reimbursement talent, and access to proprietary commercial software.
Sandoz said the deal will allow it to build a more robust ophthalmic platform that could support future product launches.
“I am pleased that we can add another high-value product to the growing Sandoz biosimilar portfolio, further strengthening our existing ophthalmology franchise,” Sandoz North America president Keren Haruvi said in the release. “The addition of Cimerli reinforces our commitment to biosimilars and represents a huge step towards our goal of pioneering patient access to more affordable and much-needed medicines in the U.S.”
The acquisition of Cimerli (ranibizumab-eqrn) is expected to close in the first half of the year.
Read more about
Click Here to Manage Email Alerts